Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terutroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R known ✓ | P21731 | 8/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 11/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terutroban SCHEMBL29378918 | 1.00 | TBXA2R (1.00) | TBXA2RTBXAS1HDAC8 | |
| Terutroban SCHEMBL43629 | 1.00 | TBXA2R (1.00) | TBXA2RTBXAS1HDAC8 | |
| Terutroban SCHEMBL29522952 | 0.91 | TBXA2R (0.84) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9252158 | 0.90 | TBXA2R (0.82) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9247892 | 0.90 | TBXA2R (0.82) | TBXA2RTBXAS1 | |
| SCHEMBL12675846 | 0.90 | TBXA2R (0.82) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9015506 | 0.89 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9246542 | 0.89 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9247825 | 0.88 | TBXA2R (0.78) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7771697 | 0.87 | TBXA2R (0.78) | TBXA2RTBXAS1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016102352-A1 | TXA2 INHIBITOR AS STIMULATOR OR INDUCER OF MHC CLASS I CROSS-PRESENTATION | INSTITUT PASTEUR (FR) | 2016-06-30 | — | — | WO | claimed |
| EP-3037106-A1 | TXA2 inhibitor as stimulator or inducer of MHC Class I cross-presentation | INSTITUT PASTEUR (FR) | 2016-06-29 | — | — | EP | claimed |
| US-12446907-B2 | Methods and apparatus for flow restoration | COVIDIEN LP (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250114334-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20250049764-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2025-02-13 | — | — | US | disclosed |
| US-12161632-B2 | Compositions and methods of treating cardiac fibrosis with ifetroban | CUMBERLAND PHARMACEUTICALS INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20230381147-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2023-11-30 | — | — | US | disclosed |
| US-20230338048-A9 | METHODS AND APPARATUS FOR FLOW RESTORATION | COVIDIEN LP | 2023-10-26 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2021202437-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 | OGLETREE MARTIN (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2016102352-A1 | TXA2 INHIBITOR AS STIMULATOR OR INDUCER OF MHC CLASS I CROSS-PRESENTATION | INSTITUT PASTEUR (FR) | 2016-06-30 | — | — | WO | disclosed |
| EP-3037106-A1 | TXA2 inhibitor as stimulator or inducer of MHC Class I cross-presentation | INSTITUT PASTEUR (FR) | 2016-06-29 | — | — | EP | disclosed |
| US-8927586-B2 | Thromboxane A2 (TP) receptor antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2011057262-A2 | TREATMENT OF INFECTIONS WITH TP RECEPTOR ANTAGONISTS | EVOLVA INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057262-A2 | TREATMENT OF INFECTIONS WITH TP RECEPTOR ANTAGONISTS | EVOLVA INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20090075976-A1 | Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | TBXA2R 3945/4885TBXAS1 2133/4885HDAC8 589/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | TBXA2R 4141/4885TBXAS1 4589/4885HDAC8 3840/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | TBXA2R 3930/4885TBXAS1 2138/4885HDAC8 649/4885 |
| US-20090075976-A1 | Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor | ACE, AGT, ACE2 | TBXA2R 1634/4885TBXAS1 534/4885HDAC8 1220/4885 |
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | TBXA2R, PTGIR, PTGFR | TBXA2R 1/4885TBXAS1 6/4885HDAC8 4093/4885 |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | TBXA2R, TBXAS1, PTGIR | TBXA2R 1/4885TBXAS1 2/4885HDAC8 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.